Elshad Hasanov, MD, PhD @HasanovLab

Machine learning-based transcriptomic signatures predict treatment outcomes across targeted therapy and immunotherapy regimens in renal cell carcinoma key findings: 🔹RNA-based signatures outperformed IMDC risk groups for PFS and OS stratification 🔹Treatment-specific transcriptomic models predicted binary outcome disease control vs progression 🔹Molecular signatures provided prognostic information beyond standard clinical risk models 🔹Supports development of precision oncology tools to personalize RCC treatment selection 📜asco.org/abstracts-pres… 📽️hasanov-lab.github.io/gallery/

Excited to share our #ASCO26 presentation from the @OhioStatePIIO @HasanovLab Biomedical Informatics PhD Student #PengLi and collaborators! Machine learning-based transcriptomic signatures predict treatment outcomes across targeted therapy and immunotherapy regimens in renal cell carcinoma 📽️hasanov-lab.github.io/gallery/ 📜asco.org/abstracts-pres… Congratulations to #PengLi and the entire @OhioStateMed @OSUCCC_James #Buckeye team: @OSUWexMed @OhioStateMedOnc @OSU_Urology #OSUPathology @eric_facs @FuatBicer #AmirMortazavi @KimrynRathmell @ZuhairMajeed @semihaxozgul #KidneyCancer #RenalCellCarcinoma #AIinMedicine #MachineLearning #PrecisionOncology #CancerResearch #ASCO #Oncology #TranslationalResearch #CodeToClinic @OSUCCC_James @ASCO @ASCOTECAG @KidneyCancer @OncoAlert @oncodaily @OncLive @urotoday

Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases @BetulGokYavuz1 @ASCO #ASCO26 Key findings: 🧠RCC brain metastases harbor distinct copy-number alterations (CNAs) compared with primary tumors. 🧬Recurrent alterations involving 8p loss, 8q gain, and 9p21.3 deletionwere enriched in brain metastases across all cancers. 📈These CNA patterns were associated with worse survival and may contribute to brain metastatic progression. 🤖Using genomic features, we developed a machine learning model that identified patients at increased risk of mortality/brain metastasis.

Excited to share our #ASCO2026 poster presentation by our postdoc alumni @BetulGokYavuz1 @UChicago 🌟 physician👩‍⚕️👩‍🔬scientist Heme/Onc fellow. Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases 📜biorxiv.org/content/10.648… 📽️ hasanov-lab.github.io/gallery/ This study could not have been possible without multi-institutional collaboration and support from @UTMDAnderson @EJonasch @WinshipAtEmory @bilenma @Hacettepe1967 @hanalioglu @HKUniversity #DavidJHShih, funding and resources @kidneycancer, @OSUCCC_James @OhioState @OSUPIIO, @HasanovLab bioinformatics team #PengLi @joseovandor @AleLaFerlita90 #KidneyCancer #RCC #BrainMetastases #PrecisionOncology #CancerGenomics #MachineLearning @ASCOTECAG @OSUCCC_James @ASCOPost @ASCO @kidneycancer @kidneycan @urotoday @OncoAlert @oncodaily @OncLive

Key findings of @ShriyaDeshmukh3 presentation at #ASCO26, the spatial transcriptomic profiling of the tumor microenvironment in metastatic RCC treated with sunitinib: 🔹Sunitinib resistance is associated with a profoundly immunosuppressive TME 🔹Enrichment of myeloid suppressive programs (SPP1+ macrophages)and T-cell exhaustion 🔹Increased angiogenesis, extracellular matrix remodeling, and hypoxia-related pathways 🔹Adaptive metabolic reprogramming emerges in resistant tumors 🔹Machine learning-derived spatial signatures predicted survival in an independent external cohort

Congratulations to our star Heme/Onc fellow, @ConquerCancerFd #ASCOMeritAwardee @ShriyaDeshmukh3, presenting at #ASCO26, the spatial transcriptomic profiling of the tumor microenvironment in metastatic RCC treated with sunitinib. If you missed the presentation: hasanov-lab.github.io/gallery/ We are grateful to our collaborators at @UTMDAnderson, @EJonasch, for leading this IIT and @KidneyCancer, @sitcancer, @OhioStatePIIO for funding correlative studies, @HasanovLab bioinformaticians @MostafaIHA @joseovandor leading analysis. #ASCO26 #SpatialTranscriptomics #TumorMicroenvironment #PrecisionOncology #MachineLearning #CodeToClinic @ASCOTECAG @OhioState @OhioStateMedOnc @OSUCCC_James @ASCO @Pelotonia

@tompowles1 @Uromigos @DrChoueiri Impressive to see the absolute risk reduction with pembrolizumab at 24 months in ctDNA+ group is 20%, vs in ctDNA- group is 7%. A new chapter for RCC adjuvant care with hopefully more sensitive tests soon. Congrats @DrChoueiri and team for this great study!

@IamLinghua @ScienceMagazine Congratulations Linghua excellent work!

🚨🚨Multiple Brain Mets Randomized Trial🚨 · Significantly less symptom burden with SRS compared to HA-WBRT · Better ADL, cognition & KPS after SRS · SRS Standard of Care 5-20 brain mets jamanetwork.com/journals/jama/…

@DrKarineTawagi @arkhaki @PriyankaChabla1 @PGrivasMDPhD @oncologydoc @shilpaonc @ERPlimackMD @DrRosenbergMSK @koshkin85 @urotoday @oncodaily @BladderCancerUS @IBCG_BladderCA @WorldBladderCan The only available data so far would support the ICI rechallege after >1y of previous ICI @ESMO_Open @BrigidaMaiorano sciencedirect.com/science/articl…

Can we stop excluding brain Mets from clinical trials. These patients need therapy. DART showed that brain Mets did not compromise safety or activity. pubmed.ncbi.nlm.nih.gov/41378983/

This interdisciplinary consensus effort sought to standardize practical management strategies of single & multiple brain mets in patients with #RenalCellCarcinoma. Authors present a framework to guide treatment decisions for patients. #AUC3 acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @OncoAlert

Mapping heterogeneity in the tumor microenvironment of #RenalCellCarcinoma through single-cell omics. #AuthorCommentary on UroToday, Single-cell and spatial technologies are uncovering profound heterogeneity in the #RCC tumor microenvironment—reshaping how we understand CD8⁺ T-cell exhaustion, myeloid diversity, and cancer-associated fibroblasts. These high-resolution insights are paving the way for better biomarkers and more precise, personalized immunotherapy in RCC. #ReadNow > bit.ly/4qYzI0Q @CellPressNews #TrendsinCancer @BetulGokYavuz1 @nkhanmam @ZuhairMajeed @mostafa96721868 @bilenma @eric_facs @HasanovLab

As 2025 comes to a close, @David_Cohn_MD, @DrRPollock and I thought we’d take a moment to celebrate stories this year that show why @OSUCCC_James is such a powerhouse against cancer. Here is a thread of 25 inspiring cancer stories in '25: 🧵

Happening now! The 7th Annual #PIIO Symposium Poster Session at Marriott OSU (3100 Olentangy River Rd, Cbus, OH). 🚀 Much more to come with the reception & Director's Address by Dr. @Zihai Li! @OSUCCC_James @Pelotonia #Immuno_Oncology

keyboard_arrow_left Previous keyboard_arrow_right Next

A perfect holiday-season read with hot chocolate & cookies ☕️🍪❄️ @trendscancer “Mapping Heterogeneity in the Tumor Microenvironment of Renal Cell Carcinoma Through Single-Cell Omics” Led by our rising star physician-scientist @BetulGokYavuz1 ✨ Free link: authors.elsevier.com/a/1mCdH8Z12ybX… Grateful for the @trendscancer editorial support, excellent reviewers, and our passionate team & collaborators @OhioStatePIIO @OSUCCC_James @OSUWexMed @kidneycancer @kidneycan @IKCCorg 🙌

keyboard_arrow_left Previous keyboard_arrow_right Next

Kidney Cancer Highlights from ESMO 2025! @IKCCorg @myESMO #ESMO25 @OncoAlert @ONCOassist ikcc.org/summary-of-kid…

🚨 Breaking RCC update from Merck (Oct 28, 2025) Two back-to-back positive Phase 3 trials for belzutifan (WELIREG®) 👇 1️⃣ LITESPARK-022 – Adjuvant setting 📍 Pembrolizumab + Belzutifan vs Pembrolizumab alone ✅ Significant DFS improvement in resected clear-cell RCC after nephrectomy 🧩 1st combo ever to beat ICI monotherapy in adjuvant RCC OS pending 2️⃣ LITESPARK-011 – Post-IO metastatic setting 📍 Belzutifan + Lenvatinib vs Cabozantinib ✅ PFS benefit & higher ORR in patients who progressed after PD-1/L1 therapy ⚠️ OS trend but not yet significant @OncoAlert @MedwatchKate

keyboard_arrow_left Previous keyboard_arrow_right Next